Amphastar PAMPH

AMPH current price
$32.79-41.79%

Capital at risk.

1W
-2.47%
1M
-9.37%
3M
-33.35%
6M
-25.16%
1Y
-41.79%
MAX
+148.43%
About Amphastar P
Ticker
info
AMPH
Trading on
info
NASDAQ
ISIN
info
US03209R1032
Industry
info
Drug Manufacturers - Specialty & Generic
Sector
info
Healthcare
CEO
info
Dr. Yongfeng Zhang Ph.D.
Headquarters
info
11570 6th Street, Rancho Cucamonga, CA, United States, 91730
Employees
info
1,761
Website
info
amphastar.com
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Metrics
BasicAdvanced
Market cap
info
$1.58B
P/E ratio
info
10.89
EPS
info
$3.01
Dividend Yield
info
0.00%
Beta
info
0.82
Forward P/E ratio
info
0
EBIDTA
info
$267M
Ex dividend date
info
-
Price & volume
Market cap
info
$1.58B
Average daily volume
info
0.5M
90-day return
info
-33.35%
30-day return
info
-9.37%
7-day return
info
-2.47%
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
10.89
Forward P/E
info
0
PEG ratio
info
2.77
Trailing P/E
info
10.89
Price to sales
info
2.18
Price to book
info
2.17
Earnings
EPS
info
$3.01
EPS estimate (current quarter)
info
$0.99
EPS estimate (next quarter)
info
$1.00
EBITDA
info
$267M
Revenues (TTM)
info
$724M
Revenues per share (TTM)
info
$14.94
Technicals
Beta
info
0.82
52-week High
info
$56.45
52-week Low
info
$32.16
50-day moving average
info
$39.26
200-day moving average
info
$43.00
Short ratio
info
6.58
Short %
info
14.71%
Management effectiveness
ROE (TTM)
info
23.85%
ROA (TTM)
info
8.67%
Profit margin
info
21.80%
Gross profit margin
info
$383M
Operating margin
info
29.83%
Growth
Quarterly earnings growth (YoY)
info
14.30%
Quarterly revenue growth (YoY)
info
5.90%
Share stats
Outstanding Shares
info
48.1M
Float
info
37.1M
Insiders %
info
22.55%
Institutions %
info
78.86%
Analyst Insights & forecasts
info

67% Buy

33% Hold

0% Sell

Based on information from 6 analysts.

Average price target

info
$47.40
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
$0.88
$0.93
5.38%
Q4 • 23Beat
$1.04
$0.96
8.33%
Q1 • 24Beat
$0.94
$0.77
22.08%
Q2 • 24Beat
$0.96
$1.00
4.00%
Q3 • 24Beat
-
-
-
Q4 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$182M
$37.9M
20.81%
Q2 • 24
$189M
$40.4M
21.41%
Q3 • 24
3.52%
6.54%
2.91%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$1.49B
$778M
52.17%
Q2 • 24
$1.55B
$818M
52.91%
Q3 • 24
3.60%
5.05%
1.41%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$69.1M
$-69.9M
$-10.7M
$63.1M
Q2 • 24
$60M
$-34.6M
$-22.8M
$46.2M
Q3 • 24
13.24%
50.52%
112.92%
26.79%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Amphastar P share?
Collapse

Amphastar P shares are currently traded for $32.79 per share.

How many shares does Amphastar P have?
Collapse

Amphastar P currently has 48.1M shares.

Does Amphastar P pay dividends?
Collapse

No, Amphastar P doesn't pay dividends.

What is Amphastar P 52 week high?
Collapse

Amphastar P 52 week high is $56.45.

What is Amphastar P 52 week low?
Collapse

Amphastar P 52 week low is $32.16.

What is the 200-day moving average of Amphastar P?
Collapse

Amphastar P 200-day moving average is $43.00.

Who is Amphastar P CEO?
Collapse

The CEO of Amphastar P is Dr. Yongfeng Zhang Ph.D..

How many employees Amphastar P has?
Collapse

Amphastar P has 1,761 employees.

What is the market cap of Amphastar P?
Collapse

The market cap of Amphastar P is $1.58B.

What is the P/E of Amphastar P?
Collapse

The current P/E of Amphastar P is 10.89.

What is the EPS of Amphastar P?
Collapse

The EPS of Amphastar P is $3.01.

What is the PEG Ratio of Amphastar P?
Collapse

The PEG Ration of Amphastar P is 2.77.

What do analysts say about Amphastar P?
Collapse

According to the analysts Amphastar P is considered a buy.